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ABSTRACT
Nanotechnology incorporated with molecular biology became a promising way to
treat cancer. The size of nanoparticles enables them to overcome the side effects noticed in
cancer treatment like chemotherapy and surgery. Various types and shapes of nanoparticles
have been synthesized and used in drug delivery to tumor sites. However, one of problems
of using these nanoparticles is the aggregation after injecting them into human body due to
flow rate of bloodstream. The coagulation and aggregation will result in clogging blood
vessel and lower therapeutic efficacy.
In this thesis, a solution to the aggregation problem was proposed, which is coating
biopolymer on nanoparticles (NPs). The experimental sections covered synthesis and
characterization of breast cancer specific targeting drug-encapsulated NPs and biopolymer
coating on the surface of Au-Fe3O4 NPs for thermal therapy. Furthermore, in vitro studies
of these NPs with breast cancer cells were also included. The specific targeting anticancer
drug-encapsulated NRs showed significant inhibition in BT-474 breast cancer cell growth.
The Au-Fe3O4 NPs has a possibility to treat cancer cells using the thermal therapy
approach.
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SECTION
1. INTRODUCTION
Invasive diseases like cancer have been a major issue for public health. The current
cancerous treatment methods such as chemotherapy or surgery still have side effects that
can cause some troubles to patients.1 Nano-biotechnology, which is the combination of
nanotechnology and biology, has become a promising way to treat cancer. Many types of
the particles within the nano-scale were synthesized through various methods. Among all
the synthetic methods that have been used, there is still a challenge for these nanoparticles.
For nanoparticles less than 100 nm in size, the long-range force between nanoparticles is
controlled by Brownian motion, which causes the collision of particles and leads them to
aggregation.2 A solution to this problem is surface modification including coating
something on the surface of particles. Coating biocompatible polymer on the particles is
an interesting technique to help increase the potential of the nanoparticles, including
anticancer drugs. It does not only increase the potential of the synthesized nanoparticles,
but also helps reduce the side effects from the drug. Anticancer drugs themselves are
considered highly toxic to cells. Therefore, specific targeting nanoparticles play an
important role in treatment to avoid the side effects to other cells. Coating polymer on the
drug may decrease toxicity and provide a surface for biomolecules like antibodies to
conjugate on, which would lead to the specific targeting treatment.
Apart from polymer-coated anticancer drug nanoparticles, the gold nanoparticles
were also used to study the hyperthermia induced treatment using the principal of thermal
therapy. One of the promising multifunctional magnetic nanomaterials is the gold
magnetite (Au-Fe3O4) nanoparticles. The magnetite nanoparticles have shown the ability
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for biomedical applications in magnetic resonance imaging and hyperthermia induced
treatment which eventually leads to cell apoptosis. Although the gold nanoparticles were
found useful to treat cancer, there is still a drawback in this strategy: low retention time in
the bloodstream, which caused the particle aggregation and clog blood vessel. To overcome
this disadvantage, coating polymer on the surface of gold nanoparticles may increase the
retention time by preventing aggregation. Therefore, this research outlines the synthesis,
characterization of anticancer drug encapsulated nanoparticles, the conjugation with
biomolecules on nanoparticles, the coating of biocompatible polymer on gold
nanoparticles, and in vitro study with breast cancer cells.
1.1. BIODEGRADABLE POLYMER-COATED PARTICLES FOR CANCER
TREATMENTS
1.1.1. Polycaprolactone (PCL). PCL is a synthetic biodegradable polymer.3 It is a
semi-crystalline, hydrophobic polymer in which the crystallinity decreases when molecular
weight increases. Due to its properties, PCL has attracted much attention for biomedical
applications.4
Ortiz et al. studied the combination of gene therapy and drug encapsulation was
expected to increase the potential of the therapy. In addition, the biodegradable polymer
like PCL has an ability to protect antitumor drugs from rapid elimination during in vivo
studies. The combination of cytosine deaminase/5-fluorocytosine (CD/5-FC) and herpes
simplex virus thymidine kinase (HSV-tk) was used in colon cancer therapy. The 5-FU drug
encapsulated nanoparticles were prepared using the solvent emulsion method. From the
results, the nanoparticles have a spherical shape with diameter of 140 ± 20 nm. Zeta
potential values also indicated that the drug was entrapped within the nanoparticles. The
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drug encapsulated nanoparticles were then tested in vitro drug release which showed a drug
release profile of up to 27% within three hours of the study in neutral pH. The rapid drug
release resulted from the leakage of the polymer surface in nanoparticles. From in vivo
study, the 5-FU drug inhibited the cell proliferation in a dose-dependent manner. The
combination of the 5-FU drug and E gene was investigated to study the cytotoxicity in
SW480 colon cancer cells. The result showed that this combination increases the
percentage of apoptotic in cells within 24 hours (83% ± 4.6%), which is greater than the
independent 5-FU loaded nanoparticles (22% ± 2.5%) and E gene (41% ± 5%). Therefore,
this study reveals a new strategy for colon cancer using the combination of drugencapsulated nanoparticles and gene therapy which is a promising in vitro study. However,
it needs to have more evidence in vivo.5
1.1.2. Poly (Lactic-Co-Glycolic Acid) (PLGA). PLGA is a copolymer, which is
the combination of polylactic acid (PLA) and polyglycolic acid (PGA). It is soluble with a
wide range of solvents such as tetrahydrofuran, ethylacetate, acetone.6
Farazuddin et al. used PLGA microsphere to entrap Perillyl alcohol (POH), which
was reported as anti-cytotoxic properties against many types of cancer. The POHencapsulated PLGA microparticles were synthesized using the oil-in-water based emulsion
solvent method. The microparticles were characterized using SEM, which revealed the
microparticle size of 768 ± 215 nm. The microparticles were further studied during in vitro
released kinetics. After 168 hours, the overall drug release was about 30%. From an in vitro
cytotoxicity experiment, the results indicated that the IC50 value of POH loaded
microparticles was higher than the drug alone. In order to confirm the efficiency of the
microparticles, they were tested in vivo using skin cancer cells. The free form of the drug
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was used to compare to the drug - encapsulated microparticles. Within 13 weeks, the
survival rate of the sample treated with microparticles was ~80%; meanwhile, the sample
treated with the POH drug alone showed only 40% survival rate. This whole study
indicated that the drug encapsulated microparticles were successfully synthesized and
provided higher efficiency than the free formed drug.7
Verderio et al. used PLGA nanoparticles to encapsulate the antitumor drug
curcumin (CUR). CUR has an ability to inhibit carcinogenesis at three stages: tumor
promotion, angiogenesis, and tumor growth. CUR interacts with TrxR, which is
overexpressed in tumor cells. TrxR is converted by NADPH oxidase and H2O2 is increased,
which finally causes the cancer cell death. However, CUR is a hydrophobic drug. In order
to overcome the problem of extremely rapid metabolism and poor absorption of CUR, this
drug needs the carrier to bring it to the tumor site. CUR was encapsulated within PLGA
nanoparticles using the solvent evaporation method. Drug - encapsulated nanoparticles
were obtained after the centrifugation. The drug-loaded nanoparticles were characterized
by TEM and SEM. The drug-encapsulated nanoparticles have a spherical shape with a
diameter of 128.37 ± 6.7 nm. The amount of CUR was calculated using UV-vis and
fluorescence spectroscopy, which showed about 80% encapsulation in the nanoparticles.
The drug-loaded PLGA nanoparticles were further used in vitro with MCF7, the HER2+
breast cancer cells. The CUR alone was used as a control. The results indicated that after
incubating MCF7 with nanoparticles for 24 hours, 50 µg/ml of nanoparticles efficiently
inhibited the tumor growth.8
1.1.3. Polylactic Acid (PLA). PLA is a thermoplastic polymer that has high
strength and high modulus. PLA is in the group of aliphatic polyester polymers.9 It is also
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degradable through the hydrolysis of ester bond where the hydrolysis rate depends on the
size and shape of particles.10
Zhu et al. used PLA to encapsulate the docetaxel (DTC) for liver cancer treatment.
The aim of this study is to enhance the drug delivery to targeted tumor sites. The drugencapsulated nanoparticles were prepared using the solvent evaporation method.
Tocopherol polyethylene glycol 1000 succinate (TPGS), a water-soluble derivative of
vitamin E, was used as an emulsifier in order to increase the drug encapsulation due to its
bulky structure and large surface area. After removing the solvent, the surface of the drug
encapsulated nanoparticles were further coated with polydopamine and then conjugated
with galactosamine to specifically target liver cancer cells. After the characterization, the
diameter of sphere-shaped NPs is ~ 209 nm. The nanoparticles were tested for DTC release
and the result showed that at the initial stage the drug released up to 30% within 2 days of
the observation. After 14 days, the cumulative DTC released was ~60%. The IC50 value of
NPs was obtained from the cell viability, which showed that NPs were ~7 fold higher than
non-targeting NPs. From in vivo results, the Gal-pD-TPGS-PLA NPs could reach the
targeted tumor site and also inhibit the tumor growth in the liver more efficiently than nontargeting nanoparticles. The overall results gave a promising strategy for liver cancer
therapy.11
In the study of PLA for breast cancer drug delivery, Jiang et al. used PLA
incorporated with TPGS to form the nanoparticles. The anticancer drug used in the study
was doxorubicin (DOX). The photosensitizer was used to induce endolysosome escape of
the delivery system to reverse the drug resistance and overcome the co-delivery problem.
This study proposed the combination of chemo-photodynamic therapy for DOX-resistant
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human breast adenocarcinoma cells (MCF-7/ADR cells). The nanoparticles were prepared
using the nanoprecipitation method which, resulted in sphere-shaped nanoparticles with a
diameter of 140.3 ± 13.45 nm. The surface of the nanoparticles was modified by
conjugating with tLyp-1 peptide .The nanoparticles were then tested in vitro drug release,
which showed that 70% of DOX was released at pH 5.5 within 96 hours of the study. After
using the laser as a trigger of the treatment, the percentage of apoptosis of nanoparticles
gave the highest percentage of other samples. The result from the in vivo study also
confirmed that the tLyp-1-NPs with the laser can inhibit the tumor growth in the mice
model more efficiently than using no laser and the non-treated mice.12
1.1.4. Dextran. Dextran is one of the polysaccharide groups which consists of
repeated monosaccharide units linked by glycosidic bonds. Dextran has been used for
particles preparation because of its nonionic charges.13
Zhang et al. proposed the use of dextran conjugated with doxorubicin in order to
improve low drug efficiency and side effects to overcome the multidrug resistance. Dox
was conjugated on the dextran via hydrazone bonds. The selective targeting was also used
in the study by grafting folate acid on dextran. The size of nanoparticles was ~148 nm in
diameter. The nanoparticles were tested for drug release in vitro at pH 5.0, which showed
DOX release up to 92% within 48 hours. The nanoparticles were further tested for cell
cytotoxicity in HepG2/DOX cells. The results indicated that the folate ligand on the
prodrugs had a selective targeting ability towards cells that express the folate receptor.
These nanoparticles were then tested in vivo and the results showed that the targeted drugcapsulated nanoparticles could expand the life of treated mice and they also had fewer side
effects to the heart.14
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1.1.5. Gelatin. Gelatin is a polymer that is not only biodegradable, and
biocompatible, but it also bio-adhesive properties. These important properties indicate that
gelatin is a material that can easily form film and particles for biomedical applications.15
Lu et al. studied paclitaxel-loaded gelatin nanoparticles for intravesicle
chemotherapy, which provides selectively drug delivery at high concentrations to tumorbearing bladders while minimizing exposure time in the system. Paclitaxel was chosen
because of its lipophilicity, which provides the ability to penetrate the urothelium more
effectively than other drugs. However, entrapping paclitaxel in micelles resulted in
lowering the drug concentration into the bladder tissue. The solutions to overcome this
problem are using a surface active agent which is capable of disrupting the micelle structure
and increasing the free fraction of paclitaxel. The drug-encapsulated gelatin nanoparticles
were synthesized using the desolvation method. The size of nanoparticles was in the range
of 600-1,000 nm. These nanoparticles were able to release the paclitaxel ~92% within two
hours. The nanoparticles can be degraded consistently by protease. The drug-encapsulated
nanoparticles can inhibit 60% of RT4 cells in 48 hours and its IC50 was lower than free
formed drug, which showed higher efficiency in inhibiting the growth of cancer cells and
was confirmed by the same trend in vivo.16
Li et al. studied the use of gelatin for encapsulating both hydrophobic CUR and
hydrophilic DOX for dual targeting HER2-overexpressing breast cancer. The nanoparticles
were synthesized using a surfactant-free method utilizing amifostine to stably link a
targeting ligand (Herceptin) to amphiphilic gelatin (AG)-iron oxide-calcium phosphate
(CaP) nanoparticles with hydrophobic CUR and hydrophilic DOX encapsulated in the AG
core and CaP shell (AGIO-CaP-CD), respectively. Gelatin entrapped the hydrophobic
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molecules by using an emulsion method. The nanoparticles were ~200 nm in diameter.
After 24 hours, DOX showed fast release (~ 60% with pH 5.0) but slow release (~ 10%
with pH 7.4), which means the nanoparticles were able to inhibit the premature DOX
release before reaching the targeted tumor site. The drug-encapsulated nanoparticles were
further tested with SK-BR-3 cells, which showed that the drug-encapsulated nanoparticles
were more effective than the drug alone and gelatin can be used as a degradation
controllable material.17
1.2. RESEARCH PROBLEM
In the context of the previous section topic, it can be said that the biodegradable
polymers are useful for drug delivery in terms of drug degradation protection, drug
encapsulation, and particle forming. The research problem for this thesis is to propose the
method to coat the anticancer drug nanoparticles and Au-Fe3O4 nanoparticles in order to
prevent them from coagulation and aggregation. Additionally, to help increase the potential
of therapeutic efficacy for delivering nanoparticles for cancer therapy. The upcoming
chapters deal with the experimental setup and their results.
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PAPER

I. BIORESPONSIVE POLYMER COATING ON TARGETED DRUG NANORODS

Tunyaboon Laemthong,a Kelly Dunlap,a Caitlin Brocker,a Dipak Barua,a Daniel Forciniti,a
Yue-Wern Huang,b and Sutapa Barua a,1

a

Department of Chemical and Biochemical Engineering

Missouri University of Science and Technology, Rolla, MO 65409
b

Department of Biological Sciences

Missouri University of Science and Technology, Rolla, MO 65409
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To whom correspondence should be addressed. Email: baruas@mst.edu. Department of
Chemical & Biochemical Engineering, 110 Bertelsmeyer Hall, 1101 N. State Street, Rolla,
MO 65409-1230
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ABSTRACT
Ineffective drug release at the target site is among the top challenges for cancer
treatment. The first challenge reflects the fact that interactions with carriers (i.e.,
nanoparticles) can denature the active ingredients of drugs by shear stress. The second
challenge is low drug release in the disease microenvironment. Here, we report a one-step
process to prepare bioresponsive polymer coated drug nanorods (NRs) from liquid
precursors using the solvent diffusion method. A thin layer (10.3  1.4 nm) of poly(caprolactone) (PCL) polymer coating was deposited on the surface of camptothecin (CPT)
anti-cancer drug NRs. The mean size of PCL-coated CPT NRs was 500.9  91.3 nm length
x 122.7  10.1 nm width. The PCL polymer coating was biodegradable at acidic pH 6 as
determined by Fourier Transform Infrared (FT-IR) spectroscopy. CPT drugs were released
up to 51.5% when PCL coating dissolved into non-toxic carboxyl and hydroxyl groups.
Trastuzumab (TTZ), a humanized IgG monoclonal antibody, was conjugated to the NR
surface for breast cancer cell targeting. Combination treatments using CPT and TTZ
decreased the HER-2 positive BT-474 breast cancer cells by 66.9  5.3 % in vitro. These
results suggest effective combination treatments of breast cancer cells using bioresponsive
polymer coated drug delivery.
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1. INTRODUCTION
Protection of molecular structures of drugs is required in order to retain its active
groups and therapeutic efficiency. For example, the lactone ring of CPT drugs is converted
to carboxylate form, which possesses high affinity to human serum albumin (HSA) at
physiological pH 7.4, and is preferentially eliminated from the body.1,2 Encapsulation of
CPT inside polymer nanoparticles prevents the conversion of CPT into the inactive
carboxylate form during blood circulation, thus increasing its likelihood of reaching the
target site.3-6 CPT has been conjugated with a variety of polymers such as β-cyclodextrin,7,8
N-hydropropylmethacrylamide (HPMA),9 polylactide (PLA),10 polyethylene glycol (PEG)
and polymethcryloyloxyethyl phosphoryl choline (polyMPC)11 to improve efficacy. There
are other formulations such as liposomes consisting of floxuridine and CPT-analog
irinotecan,12 and micelles comprising of CPT derivative SN38.13 The nanostructured
derivatives of CPT increase systemic exposure to CPT and anti-cancer activity in patients;
however, the side effects are diarrhea, hepatic toxicity and renal failure.14,15 In addition,
most nanoparticle-drug conjugates suffer from aggregation with hydrophilic and
hydrophobic backbone of nanoparticles,16 and, therefore, low drug release.
In contrast, in the present work, we have developed a method to coat a
bioresponsive polymer on elongated drug NRs. While conventional nanoparticles are made
of lipids, metals and polymers, we prepared rod-shape nanoparticles using pure anti-cancer
drugs, and deposited a thin layer (10.3 ± 1.4 nm) of bioresponsive polymer coating on drug
NRs. Recent studies have shown that NRs enhance drug delivery as reflected in improved
blood circulation time,17 specific receptor binding18 and cellular internalization by target
cells.18 Theoretical models and in vivo biodistribution studies support these experimental
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outcomes.17,19,20 Cationic cross-linked PEG hydrogel NRs are internalized by HeLa cells
more rapidly than symmetrical shaped NPs.21 Mesoporous silica NRs of 450 nm length are
taken up more rapidly than 250 nm rods or 100 nm spherical particles by A375 human
melanoma cells.22 Rod-shaped particles can avoid phagocytosis depending on the initial
contact angle to the macrophages.23 The adhesion strength of non-spherical particles
towards the blood vessel wall is higher than spherical NPs, as shown in both experimental
setting, and theoretical modeling.19,24-28 Accordingly, we prepared drug NRs in this work.
We used the solvent diffusion method to prepare CPT NRs of 500.9 ± 91.3 x 122.7 ±10.1
nm size in large quantities.29
We encapsulate CPT drug NRs with a bioresponsive polymer, PCL. This polymer
is a FDA-approved biodegradable aliphatic polyester, and is well-known for hydrolytic
cleavage of ester groups, and its non-toxicity.30 Nanoparticles composed of PCL polymer
have been shown to exhibit increased blood circulation time, and reduced clearance by
reticuloendothelial system (RES).31 PCL microspheres loaded with bovine serum albumin
(BSA) protein released up to 60.5% of BSA in vitro.32 CPT, Doxorubicin and Taxol-loaded
PCL microspheres efficiently released the loaded drugs from microspheres that resulted in
a higher degree of cancer cell growth inhibition than free drugs.33-35 One drawback of these
polymer-drug conjugates is drug’s aggregation with polymers,16 and, therefore, low drug
release. To overcome these issues, we introduce a simple and rapid technique of interfacial
polymer deposition on the surface of pure drug NRs in large quantities. The significance
of our systems is that the NP shape provides greater contact surface area than conventional
spherical NPs, and thus, ensures greater receptor ligand interactions for binding.36 We
hypothesize that depositing a thin layer of PCL polymer on the surface of drug NRs would
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not only protect drugs from degradation but also allow release of drugs at the target site
due to specific receptor binding. We deposit a PCL coating from liquid precursors
surrounding CPT NRs simultaneously during the drug NR formation.
Our nanocarrier system aims at selective breast cancer cell targeting by human
epidermal growth factor 2 (HER-2) protein specific antibody conjugation. TTZ (Herceptin;
Genentech) monoclonal antibody (mAb) binds to HER-2 overexpressed at the cell
membrane by many cancer cells, including breast cancer cells.37 It is shown that TTZconjugated polystyrene NRs accumulate in breast cancer cells by multivalent interactions
with HER-2 receptors.26 TTZ reduces proliferation of breast cancer cells by binding to the
extracellular domain of HER-2 receptors, preventing HER-2 dimerization, and thereby
inducing subsequent cell cycle arrest in G1.38 In this study, we simultaneously delivered
CPT and TTZ drugs using PCL coated NRs to achieve synergistic inhibition effects on
breast cancer growth at low concentrations.
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2. MATERIALS AND METHODS

2.1 SYNTHESIS OF PCL POLYMER COATED CPT NRs
All reagents were purchased from Sigma-Aldrich unless otherwise specified. We
deposited a thin layer of continuous PCL polymer (14,000 Da) film on CPT NRs using the
solvent diffusion method.29 Briefly, 1 ml each of 10 mg/ml of CPT in DMSO and 1 mg/ml
of PCL polymer in toluene were added to a 20 ml of reverse osmosis (RO) water using a
syringe pump. Residual toluene was removed by stirring (300 rpm) the CPT-PCL NR
suspension overnight at room temperature (R.T.; ~22oC). DMSO was removed by
centrifugation at 3,000 rcf, followed by five times washing using RO water. PCL-coated
CPT (CPT-PCL) NRs were freeze-dried, weighed and stored at 4oC. CPT concentrations
were measured, and quantified by reading absorbance at 366 nm using a plate reader
(BioTek Synergy), and the CPT calibration curve.18,29 The theoretical content of PCL
weight in CPT-PCL NRs was calculated based on the weight of freeze-dried particles and
CPT amount. Percent encapsulation efficiency of CPT and PCL were calculated based on
their initial mass of samples.
2.2 CHARACTERIZATION OF CPT-PCL NRs
The morphology and size of CPT-PCL NRs were examined under transmission
electron microscope (TEM; Tecnai F20) at an accelerating voltage of 120 kV. A drop of
10 µl CPT-PCL solutions in water was air-dried on carbon-coated copper grids (Tedpella).
The NR diameter, NR length, and thickness of the polymer coating were measured using
ImageJ (version 1.45S, NIH, USA). Uncoated CPT NRs were imaged using a scanning
electron microscope (SEM; Helios Nanolab 600 FIB). The surface charges of NRs in PBS
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were determined by dynamic light scattering using a NanoSeries Zetasizer ZS 90 (Malvern)
and the backscattering detection at 90o. The zeta potential was measured for 15 runs. Data
was analyzed using means and standard deviations of three concentrations.
2.3 DEGRADATION OF PCL COATING AND STABILITY OF LACTONE FORM
OF CPT IN CPT-PCL NRS
The degradation of PCL coating, and conversion between lactone and carboxylates
in CPT were analyzed by FT-IR spectroscopy. The disappearance of ester groups in PCL
backbone, and appearance of carboxyl and hydroxyl groups were studied using FT-IR
spectra. Briefly, CPT-PCL NRs were incubated for 72 h at 37oC in PBS at pH 6. Samples
were freeze-dried to sublimate any water, and ground at 1:100 weight ratio with FT-IR
grade potassium bromide (KBr; Alpha Aesar). Hydrolytic degradation was monitored by
comparing the intensity of ester, alcohol and carboxyl bands at t=0 and 72 h for the same
amount of PCL in NRs. To evaluate the conversion of active lactone rings into inactive
carboxylic acids in coated NRs, CPT NRs alone without PCL coating was used as a control.
The FT-IR absorbance spectra were obtained for 32 scans over the range of 4000 – 400
cm-1 using a Thermo Nicolet Nexus 470 FT-IR. Background noises were subtracted from
the spectra. All spectra were analyzed using EZ OMNIC E.S.P v.5.1 software.
2.4 QUANTIFICATION OF CPT DRUG RELEASE
CPT drug release was conducted by exposing CPT-PCL NRs to phosphate buffered
saline (PBS) at pH 6 (to mimic the cancer microenvironment) and pH 7.4, and at 37 oC.
PBS of 500 µl were sampled at different time intervals of t = 0, 0.5, 2, 4, 8, 24, 36 and 72
h. CPT drug concentrations, that were released to the buffer, were measured using
absorbance at 366 nm and CPT standard curve. (These experiments were not run in
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presence of fetal bovine serum (FBS) because FBS has high spectroscopic background
noises).
2.5 CONJUGATION OF ANTIBODY ON THE SURFACE OF CPT-PCL NRs
TTZ antibody (Genentech) was conjugated to the surface of CPT-PCL NRs by
coupling primary amines of TTZ with ester groups of PCL forming amide bonds. Briefly,
10 mg/ml TTZ solution was prepared in PBS of pH 7.4. 10 mg CPT-PCL NRs were added
to 1 ml of TTZ solution, mixed, and incubated at R.T. The unreacted reagents were
separated using 100 kDa membrane filters (EMD Millipore Amicon Ultra-0.5). The
supernatants were collected by centrifugation at 1,000 rcf, and analyzed by the BCA
protein assay (Pierce Thermo Scientific). Bovine serum albumin (BSA) was used to
prepare HER-2 non-targeted CPT-PCL-BSA NRs.
2.6 IN VITRO CELL GROWTH INHIBITION
The effectiveness of combination treatments using CPT-PCL-TTZ NRs was
evaluated in HER-2 positive BT-474 breast cancer cells (ATCC) and HER-2 negative cell
line MDA-MB-231 (ATCC). The cells were cultured in Hybri-Care (ATCC), and RPMI
1640 (Life Technologies), respectively supplemented with 10% FBS (Corning) and 1%
(100 units/ml) Penicillin-Streptomycin (Gibco) at 37oC and 5% CO2. Cells were plated in
96-well tissue culture plates (Corning) at a density of 10,000 cells/well in 200 µl respective
medium. After 18 h of growth, 10 µl of NRs were added to the medium. The final
concentrations of CPT were 0.1, 0.2, 0.5, 1, 2, 5 and 10 µg/ml. The corresponding PCL
concentrations were 2.9 5.8, 14.6, 29.1, 58.2, 145.5 and 291.1 µg/ml, respectively, and
TTZ concentrations were 0.4, 0.8, 1.9, 3.8, 7.5, 18.8 and 37.7 µg/ml, respectively. CPTPCL-BSA was used as HER-2 non-specific control. Cells were also treated with the same
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concentrations of PCL solutions to determine its cytotoxic effects. Cells treated with 10 µl
of PBS were used as positive controls. 3 h later, the medium was replaced with fresh
medium. After 72 h, the plates were centrifuged at 100 rcf for 15 min. The supernatant was
discarded. Live cells were stained with 2 µM calcein AM (Life technologies) in PBS by
incubating at R.T. for 30 min. The fluorescence intensity (F.I.) of calcein AM was
measured using 485/528 excitation/emission filters using the plate reader (BioTek Synergy
2). The percentage inhibition in cell growth was calculated using the following equation
(1):
% 𝑖𝑛𝑖ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑒𝑙𝑙 𝑔𝑟𝑜𝑤𝑡ℎ =

𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 −𝐹.𝐼.𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠

× 100

(1)

To examine that the cell growth inhibitory effects were induced by NRs
intracellularly, BT-474 cells were incubated with CPT-PCL-TTZ NRs for 6 h at 37C in
8-well glass chambers (Lab-Tek). TTZ was labeled with Alex Fluor 594 dye according to
the manufacturer (Molecular Probes)’s protocol. After 2 h of NR incubation, the cells were
washed with PBS three times to remove unbound particles, and re-incubated with medium
for 4 h. Cells were imaged using a scanning laser inverted confocal microscope (Ti-Eclipse;
Nikon) and 40x objective. The excitation/emission used for CPT and Alexa Fluor 594 were
360/400 and 590/617 nm, respectively.
2.7 STATISTICAL ANALYSIS
Each experiment was carried out with three independent experiments of at least
triplicate measurements. The mean differences and standard deviations were evaluated.
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3. RESULTS
3.1 PREPARATION OF A THIN LAYER OF PCL COATING ON CPT NRs
We developed an engineering technique based on the solvent diffusion method to
prepare PCL coated CPT NRs of 500.9 ± 91.3 nm x 122.7 ± 10.1 nm in length and width,
respectively (Fig. 3.1 (a)). This process involved 3-steps: phase separation, CPT NR

a

b

c

Figure 3.1: TEM images of CPT-PCL NRs. (a) Image showing homogeneous distribution of CPTPCL NRs. (b) Magnified view of a thin (~10 nm; arrows) PCL polymer film on CPT NRs. (c)
Polymer coating thickness
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formation and PCL deposition. CPT NRs were formed because of phase separation from
the DMSO oil phase into water under mild stirring (~300 rpm).18,29 At the same time,
continuous PCL polymer films were coated on CPT NRs by virtue of van der Waals
attractive forces between CPT NR surface and PCL polymer under low shear stress.39 The
combination of adhesive and shear forces spread the polymer thinly over CPT NRs. A thin
layer of 10.3±1.4 nm PCL coating was formed surrounding the CPT NR (Fig. 3.1(b) and
Fig 3.1(c)). This is a soft coating technique that does not require high mechanical agitation,
sonication or vibration, thus preventing any structural damage of drugs. The encapsulation
efficiency of drug: copolymers were reported 0.02 to 0.15.40 Zeta potentials of CPT NRs
and CPT-PCL NRs were measured as -26.8 ± 7.71 mV (Fig. 3.2(a)) and -15.5 ± 3 mV (Fig.
3.2(b)) in PBS, respectively. An increase in zeta potential for CPT-PCL NRs indicates the
deposition of the polymer on the surface of CPT NRs.
3.2 DEGRADATION OF PCL COATING USING FT-IR SPECTROSCOPY
The degradation of functional groups of PCL coating was determined by FT-IR
analysis (Fig. 3.3). The infrared spectra of CPT-PCL NRs were compared before (t=0; Fig.
3.3, top, dotted line) and after (t=72 h; Fig. 3.3, middle, solid line) incubation in PBS at pH
6 that mimics the slightly acidic cancer microenvironment. The presence of strong band at
1746 cm-1 is due to the presence of ester carbonyl group that corresponds to the –CO
stretching in PCL polymer coating before degradation (dotted line). The band intensity at
1746 cm-1 decreased after 72 h due to hydrolytic cleavage of ester bonds at pH 6 (solid
line). The peak at 1288 cm-1 represents C-C and C=O stretching in the PCL polymer
backbone,41 which decreases in intensity at t=72 h. The peaks at 2860 and 2930 cm-1
correspond to the characteristic absorption of the C-H stretching bonds of ԑ-CL. The
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appearance of two peaks at 1460 and 2370 cm-1 in t=72 h spectra are characteristics of OH functional group in carboxylic acid (-COOH) indicating the hydrolysis of ester bonds.

a

b
Figure 3.2: Surface zeta potential of CPT NRs (a) before PCL coating, and (b) after PCL coating as
analyzed using DLS. Three colored lines indicate three replicates with a symmetric distribution of
zeta potential.
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OH functional group in carboxylic acid (-COOH) indicating the hydrolysis of ester bonds.
The peak at 3420 cm-1 indicates the presence of H-O-H stretching in water that increases
in intensity slightly at t=72 h. The absorption band of hydroxyl group is also present at t=0
h with a slightly shorter peak, which, may be, due to absorption of moisture from the

Figure 3.3: FT-IR graphs of CPT-PCL NRs at t=0 (dotted line), t=72 h (solid line) and CPT NRs
without any coating
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atmosphere. The FT-IR spectra of CPT NRs without PCL coating (Fig. 3.3, bottom, dash
line) shows carbonyl stretching for cyclic ester (lactone) at 1630 cm-1 and C-C(=O)-O
stretching for carboxylate at 1294 cm-1.42 We calculated the ratio of intensity peaks of
lactone: carboxylate that was 2.81 in uncoated CPT NRs. This ratio of lactone: carboxylate
decreased to only 0.8 in CPT-PCL NRs suggesting the protection of an active form of
lactone rings underlying the PCL coating.
3.3 CPT DRUG RELEASE WITH PCL COATING DEGRADATION
The percentage of CPT release at different time intervals is shown in Fig. 3.4 as
calculated using the CPT standard curve (Fig. 3.5). A slow release was observed at pH 6

Figure 3.4: Cumulative percentage of CPT drug release from CPT-PCL NRs in PBS buffer at
pH 6 (solid line, solid points) and pH 7.4 (dotted line, open points), and at 37C versus time
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(solid line) with 8.2% CPT release in the first 0.5 h following 32.6% release after 8 h, and
51.5% after 72 h. The release rate is comparable with the release patterns of CPT from
poly(D,L-lactide-co-glycolic acid) (PLGA) microspheres,43 and HCPT-1 from PCLLA-

Figure 3.5: The CPT standard curve was used to measure the drug concentrations

PEG-PCLLA.33 At pH 7.4 (dotted line), the release profile was slower, and it needs almost
72 h to reach ~30% release, indicating the coating effect of bioresponsive PCL barrier.
CPT was released from PCL-coated NRs at pH 6 by hydrolytic disruption of PCL coating
and the drug’s diffusion.
3.4

PREPARATION

OF

ANTIBODY

TARGETED

CPT-PCL-TTZ

NRs

TTZ antibody was conjugated on the surface of CPT-PCL NRs by amide bond
formation between the ester groups of polymer and amines on the antibody. The advantage
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of this method is the avoidance of preliminary modifications of the antibody such as
activation by carbodiimide that reduces its activity.46 TTZ covalent binding will help to
deliver the NRs at breast cancer cells. The encapsulation efficiency was expressed as
the weight ratio among CPT, PCL and proteins (TTZ or BSA) incorporated in NRs (Table
3.1). The protein concentrations were measured using the BCA protein assay and BSA
standard curve (Fig. 3.6). The weight ratio of CPT: PCL: TTZ and CPT: PCL: BSA were
calculated as 12: 1: 9 and 13.9: 1: 9.4, respectively (Table 3.1). Table 3.2 shows the
percentage encapsulation of CPT, PCL, TTZ and BSA in respective NRs.

Figure 3.6: The BSA standard curve was used to measure protein concentrations.
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Table 3.1: Characterization of CPT-PCL-TTZ and CPT-PCL-BSA NR
conjugates
CPT in CPT-PCL-TTZ NRs, mg

4.8 ± 1.3

PCL in CPT-PCL-TTZ NRs, mg

0.4 ± 0.05

TTZ in CPT-PCL-TTZ NRs, mg

3.7 ± 1.6

CPT: PCL: TTZ (w: w ratio)

12 : 1 : 9

CPT in CPT-PCL-BSA NRs, mg

5 ± 0.8

PCL in CPT-PCL-BSA NRs, mg

0.36 ± 0.9

BSA in CPT-PCL-BSA NRs. mg

3.4 ± 1.7

CPT: PCL: BSA (w: w ratio)

13.9 : 1 : 9.4

Table 3.2: Encapsulation efficiency for CPT, PCL, TTZ and BSA in NR forms
Component

% encapsulation/ conjugation efficiency

CPT

49.2 ± 1.1

PCL

39.9 ± 5.9

TTZ

41.1 ± 1.8

BSA

33.7 ± 1.8

3.5 INHIBITION OF BREAST CANCER CELL GROWTH BY CPT-PCL-TTZ NRs
The therapeutic activity of CPT-PCL-TTZ NRs was evaluated in HER-2 positive
BT-474 (Fig. 3.7) and HER-2 negative MDA-MB-231 cells (Fig. 3.8) at varying
concentrations. These are the previously reported doses of CPT in human breast cancer
cells.7,8,29,47 The NRs inhibited the growth of HER-2 positive BT-474 cells in a dose
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dependent manner. The combination of CPT and TTZ using CPT-PCL-TTZ NRs inhibited
up to 61.6% BT-474 cell growth at 10 µg/ml. At this concentration, CPT-PCL-TTZ NRs
inhibited the cell growth 1.5 fold more than CPT-PCL-BSA NRs. The difference in growth
inhibition between CPT-PCL-TTZ and CPT-PCL-BSA indicates the antibody dependent
growth inhibition effects of TTZ on HER-2 positive BT-474 cells.48,49 Surprisingly HER2 negative MDA-MB-231 cell line was also sensitive to the NRs (Fig. 3.8). No difference
between CPT-PCL-BSA and CPT-PCL-TTZ was found in these cells, indicating nonspecific CPT-evoked growth inhibition.
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Figure 3.7: Growth inhibition curves of HER-2 positive BT-474 cells as determined by calceinAM live dead assay after 72 h incubation. Results are expressed as a percentage of PBS-treated
control cells versus doses of CPT in CPT-PCL-TTZ NRs. The data represent average and
standard deviation of ten treatments in three independent experiments.
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Figure 3.8: Growth inhibitory effects of CPT-PCL-TTZ NRs on HER-2 negative MDA-MB231 cells. No difference between CPT-PCL-TTZ and CPT-PCL-BSA control indicates nontargeted CPT mediated cytotoxicity only in MDA-MB-231 cell
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4. DISCUSSION
Our proposed polymer-coated drug NRs have advantages over uncoated drugs in
that they can avoid rapid body clearance, have fewer side effects in normal healthy cells,
and can protect drugs from premature degradation. At physiological pH, the unstable Ering lactone in CPT is converted to carboxylate form, which possesses high affinity to
human serum albumin (HSA) and is preferentially eliminated.1,2 This is a clinical hurdle to
CPT therapeutic efficiency. Encapsulation of CPT inside PCL polymer coating prevents
CPT from being converted into the inactive carboxylate form during blood circulation, thus
increasing its likelihood of reaching the tumor intact.50,51 As it is observed from the FT-IR
data (Fig. 3.3) that the PCL coating undergoes hydrolytic degradation producing non-toxic
by-products (alcohol and water). Slow degradation of the polymers released CPT drugs
from NRs at pH 6 (Fig. 3.4; solid line). At pH 7.4, PCL polymer coating does not allow for
fast CPT penetration (Fig. 3.4; dotted line).
The elongated NR design allows for long circulation time in the body,24,26,52-54 and
multivalent interactions with tumor cells,21,55,56 increasing the probability of receptorligand interactions. It is shown that the active targeting of breast cancer cells using the
similar dimension of NRs of CPT with TTZ attached to the breast cancer cell surface. 18,29
Due to the fluid dynamics induced by the unique rod shape, these nanoparticles flow along
the edges of blood vessels. By flowing along the sides of blood vessels, nanoparticles fall
to the tumor due to gaps in the endothelial cell wall between the tumorous tissue and blood
vessels.57 The layer of TTZ antibody on the surface of NRs offers additional feature of
targeted therapy.
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The tumor microenvironment is slightly more acidic (pH ~6) than the blood (pH
7.4).58,59 We simulated the condition using PBS at pH 6 and determined the effects on the
stability of NRs. The release of CPT in the first 30 minutes was minimal, with only 7.4%
of the total CPT drugs in NRs being released (Fig. 3.4; solid line). The polymer coating
begins to disintegrate, releasing ~40% of total CPT in 24 h and more than 50.8% in 72 h.
Interaction with cancer cells is important for most nanoparticles reaching the target
site. By changing nanoparticle geometry from spherical to rod-shape, receptor-ligand
interactions can be enhanced up to 2.5 fold by multivalency effects.18 We accomplished
active targeting by conjugating TTZ to the surface of CPT-PCL NRs. By using both CPT
and TTZ, which use different mechanisms of actions of cytotoxicity, we find increased
therapeutic efficacy over those of traditional monotherapies. CPT is a topoisomerase I
(topoI) inhibitor that selectively affects cancer cells by exerting S-phase cytotoxicity and
G2-M cell cycle arrest.1,2 TTZ induces cell cycle arrest in the G1 phase leading to
apoptosis.37,38 While CPT is cytotoxic and the single agent therapeutic response rate of
TTZ is low (~26%),6,33,37,48,49,60-62 the combination approach is more effective in treating
cancers than monotherapies, as the probability of acquiring resistance to two simultaneous
treatments is the square of the probability of resistance to a single agent.
We observed that HER-2 negative MDA-MB-231 cell line was sensitive to NRs
(Fig. 3.8). No difference between CPT-PCL-BSA and CPT-PCL-TTZ was found in these
cells. We conjecture that this might be due to effective non-specific endocytosis in in vitro
setting. We anticipate difference in targeting efficiency shall be observed in in vivo setting.
Collectively, our results support a purely cytostatic effect of these drugs in vitro, we are
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currently at the stage of performing in vivo experiments to examine this combination in
mice xenograft models.
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5. CONCLUSIONS
We have developed a simple method of thin (10.3±1.4 nm) layer of bioresponsive
PCL polymer coating on CPT anti-cancer drug NRs. As the drug molecules precipitated
out of its organic solvent into an aqueous phase, the molecules aggregated and formed NRs.
The PCL polymers spread thinly over drug NRs due to van der Waals and hydrogen
bonding effects. This process did not produce any adverse mechanical effects to prepare
the NRs, thereby, retaining active structures of therapeutic drugs. One merit of our method
is the preparation of PCL-coated CPT NRs of (500.9±91.3 x 122.7±10.1) nm size in large
quantities. We characterized the degradation of CPT-PCL NRs using FT-IR analysis, and
release of CPT in a simulated pH condition in caner microenvironment. Conjugation of
TTZ to the surface of CPT-PCL NRs significantly inhibited the growth of BT-474 breast
cancer cells. Overexpression of HER-2 increases breast cancer cell proliferation in part by
transactivation of enhanced growth factor receptor (EGFR) signaling.37,48,61 Blocking of
HER-2 by selective TTZ binding proved to suppress the cells growth. In vivo studies are
needed for therapeutic efficacy. Nonetheless, our current results found thus far are
promising and continue to shed light of the inherent benefits of improved breast cancer
therapy
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II. POLYMER COATING ON Au-Fe3O4 NANOPARTICLES
ABSTRACT
Nanoparticle synthesizing methods have been widely studied for cancer treatment.
However, aggregation of nanoparticles inside the blood vessel remains a problem for
cancer treatment. The aggregation of the nanoparticles inside the vessel reduces the
potential and ability of the nanoparticles by blocking access to the targeted site and
removing them from the body. Here, we report a simple and fast method to solve the
problem by depositing a thin layer of biocompatible polymers on the surface of
nanoparticles to reduce the chance of collision of the nanoparticles, which will prevent
them from aggregation. The thin layer (1.81 ± 0.60 nm) of poly-l-lysine (PLL) and
polyethylene glycol (PEG) was deposited on Au-Fe3O4 nanoparticles. The average size of
the nanoparticles was 58.27 ± 7.48 nm. The nanoparticles were uptaken by the breast
cancer cells. The Au-Fe3O4 nanoparticles showed the toxicity to the breast cancer cells at
500 µg/ml. The NIR laser with Au-Fe3O4 nanoparticles was able to induce the
hyperthermia effect to cells. These results suggest the optimal concentration of Au-Fe3O4
nanoparticles and the coating method to use in breast cancer treatment using the
hyperthermia effect.

42
1. INTRODUCTION
Current cancer treatment methods have been focusing on noninvasive techniques.
One of the interesting approaches is the hyperthermia effect. The hyperthermia effect
occurs when the temperature is in the range of 39-42 oC for at least 1 hour.18 At this
temperature range, the effects (including inhibition of radiation that induces the damage
repair, changes in perfusion, and re-oxygenation) are able to improve the therapy in the
tumor sites.19 One approach to the method of inducing hyperthermia effect is delivering
metal nanoparticles to the tumor site. Gold nanoparticles have been studied due to their
biocompatibility to the human body and cost-effective approach for cancer treatment.20
Surface plasmon resonance (SPR) is the phenomenon that the electromagnetic field at a
certain wavelength stimulates the free electrons across the surface of gold nanoparticles.
As a result of SPR, the particles released the heat after they absorbed the electromagnetic
field.21 Various types of gold nanoparticles have been synthesized and used for
hyperthermia-inducing therapy, such as gold nanoshells,22 gold nanorods,23 and gold
nanospheres.24 Near Infrared (NIR) wavelength (800-1300 nm) plays an important role in
order to induce the SPR of gold nanoparticles because gold nanoparticles highly absorb the
wavelength in this region.25
Even though gold nanoparticles were found useful for cancer treatment, there is
still a drawback to this method. The disadvantage is the low retention time, as nanoparticles
started to accumulate in the tumor site at high concentration.26 In order to solve this
problem, we coated the surface of the gold nanoparticle with biocompatible polymer PLL
and PEG to prevent them from aggregation. PLL is the biocompatible cationic polymer
that provides active amino groups that are useful for drug delivery and cell adhesion.27
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Coating PLL on the surface of metal nanoparticles resulted in increased retention time of
silver nanoparticles.28 PEG is a neutral polyether, which is water soluble and has an ability
to form two phases with other polymers. In addition, this polymer is non-toxic to cells.29
In this study, we coated Au-Fe3O4 nanoparticles with PLL together with PEG to
create a polymer layer around the gold nanoparticles. We hypothesize that coating polymer
on the surface of these nanoparticles will result in increased the retention time and
prevention from aggregation, which would help increase the therapeutic efficacy for cancer
treatment.
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2. MATERIALS AND METHODS
2.1 PLL COATING ON Au-Fe3O4 NANOPARTICLES
All reagents were purchased from Sigma-Aldrich unless otherwise specified.
Briefly, 25 mg/ml of bare gold nanoparticles was prepared in 1 ml of water. Then, 653 µL
of 0.1% w/v of PLL was added to nanoparticles. After 1 minute of mixing, 250 µl of 1%
w/v PEG was added to the mixture per 10 ml of mixture. The whole suspension was stirred
for 5 minutes. The excess PLL and PEG were removed by centrifuging at 5,000 rcf for 30
minutes. The amount of PLL was quantified using Trypan Blue assay, which was modified
from Grotzky et al.30
2.2 PLL- Au-Fe3O4 NANOPARTICLE CHARACTERIZATION
The morphology and size of nanoparticles were characterized by using a
transmission electron microscope (TEM, Tecnai F20) at an accelerating voltage of 120 kV.
A drop of 10 µl of sample was air-dried in carbon coated copper nanogrid (Tedpella). The
size of Au-Fe3O4 and polymer coating thickness were measured using ImageJ (version
1.45S, NIH, USA).
2.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES
To estimate the optimal concentration of Au-Fe3O4 nanoparticles, BT-474 cells
were cultured in Hybri-Care (ATCC) media supplemented with 10% Fetal Bobine Serum
(FBS) and 1% (100 units/ml) Pennicillin-Streptpmycin (Corning) at 37 oC and 5% CO2
respectively. Then, cells were plated in a 96- tissue culture well plate at a density of 10,000
cells per well in 200 µl of media. After 18 hours of growth, Au-Fe3O4 nanoparticles were
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added to the medium. The final concentrations of Au-Fe3O4 nanoparticles were 500, 100,
50, 10, 5 and 1 µg/ml. The media was replaced to remove non-uptaken nanoparticles after
3 hours of incubation. After 72 hours, the plate was centrifuged down at 100 rcf for 15
minutes. The supernatant was discarded. Live cells were stained with 2 µM of Calcein AM
(Life technologies) in PBS. The percentage of dead cells was calculated using equation 1.
% 𝑖𝑛𝑖ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑒𝑙𝑙 𝑔𝑟𝑜𝑤𝑡ℎ =

𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 −𝐹.𝐼.𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝐹.𝐼.𝑃𝐵𝑆 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠

× 100.

(1)

In order to examine the cell apoptosis effects induced by PLL-coated gold
nanoparticles, BT-474 cells were incubated with PLL-coated gold nanoparticles for 3 hours
at 37 oC in a 96-tissue culture well plate. After the incubation, the cells were washed with
sterilized PBS three times to remove non-uptaken nanoparticles.
2.4 IN VITRO CELL APOPTOSIS STUDY
The apoptosis study of PLL-coated gold nanoparticles was evaluated using HER2+
breast cancer cell line (ATCC). The cells were plated in a 96-tissue culture well plate at a
density of 10,000 cells per well in 200 µl of media. After 18 hours of growth, 10 µl of PLLcoated gold nanoparticles was added to the medium. The final concentrations of PLLcoated nanoparticles were 100, 50, 10, 5 and 1 µg/ml. The media was replaced with fresh
media to remove the non-uptaken nanoparticles after 3 hours of incubation. Then, the cells
were treated with a NIR wavelength laser (790 nm) at 1 W/cm2 for 1 minute. After 72
hours, the plate was centrifuged down at 100 rcf for 15 minutes. The supernatant was
discarded. Live cells were stained with 2 µM of Calcein AM (Life technologies) in PBS.
The plate was then incubated at R.T. for 45 minutes. The fluorescent intensity (F.I.) was
measured using 485/528 filters using a plate reader (BioTek Synergy 2).
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RESULTS
3.1 CHARACTERIZATION OF PLL-Au-Fe3O4 NANOPARTICLES
Because the shape of Au-Fe3O4 nanoparticles is both hexagonal and square, the
equivalent diameter was used to measure the size of nanoparticles. The equivalent diameter
of Au-Fe3O4 nanoparticles is 58.27 ± 7.48 nm, as shown in Fig 3.1 (a), while the PLL-AuFe3O4 nanoparticles diameter is 60.56 ± 7.18 nm. The thickness of the PLL coating is 1.81
± 0.60 nm as shown in Fig 3.1 (b).

a

b

Figure 3.1 : TEM image of (a) uncoated Au-Fe3O4 nanoparticles. (b) PLL coating on Au-Fe3O4
nanoparticles.

3.2 CELLULAR UPTAKE OF Au-Fe3O4 NANOPARTICLES
Despite the size of Au-Fe3O4 nanoparticles, the intracellular uptake of Au-Fe3O4
nanoparticles were examined. The microscopic images confirmed the delivery of
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nanoparticles inside the cells (Fig.3.2), indicating that the nanoparticles were uptaken
inside the cells. No nanoparticles were found outside the cells.

a

b

Figure 3.2 : Microscopic images of (a) Cellular uptake of 100 µg/ml of Au-Fe3O4 nanoparticles
inside BT-474 cells. (b) PBS treated BT-474 cells

3.3 BT-474 CELL CYTOTOXICITY WITH Au-Fe3O4 NANOPARTICLES
According to Fig. 3.3, the Au-Fe3O4 nanoparticle at low concentration (up to 100
µg/ml) was found to have negligible cytotoxic effect to the cells, whereas the percentage
of cell death increased to ~40% at 500 µg/ml, which might be the effect of the aggregation
of nanoparticles.
3.4 EFFECTS OF THE Au-Fe3O4 NANOPARTICLE WITH NIR LASER TO
BT-474 CELLS
After the optimal concentration of Au-Fe3O4 nanoparticles that did not cause
cytotoxicity to BT-474 cells was known, the cells were incubated within that concentration.
The cells were then exposed to NIR laser for 1 min. The results indicated that after the AuFe3O4 nanoparticles, uptaken cells were exposed to the laser, the percentage of death cells
increased in every concentration, as shown in Fig. 3.4. The laser-PBS treated cells were
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used as a control. The laser itself did not show toxicity to cells but the cells with the same
concentration without using laser showed a negligible effect of toxicity to cells. For
example, at 100 µg/ml of Au-Fe3O4 nanoparticles, the laser treated cells showed ~45% of

Figure 3.3: Au-Fe3O4 nanoparticle toxicity with BT-474 cells

cell death while non-laser treated cells showed only ~24% of cell death. The same trend
also occurred at other concentrations of Au-Fe3O4 nanoparticles. This can be the evidence
to confirm that the NIR laser can be used to induce the hyperthermia effect, which caused
the cell death.
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Figure 3.4: % BT-474 cell death after adding Au-Fe3O4 nanoparticles and exposing to NIR
laser
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4. DISCUSSION
The simple method to coat the surface of Au-Fe3O4 nanoparticles using both
biopolymers, which are PLL and PEG was proposed. The particles themselves aggregated
within the cells after they were uptaken by the cells. The microscopic images confirmed
the cellular uptake of the nanoparticles. Most of the nanoparticles were found inside the
cells. We also found that at the final concentration of 500 µg/ml, Au-Fe3O4 nanoparticles
showed some cytotoxicity to BT-474 cells. This was due to nanoparticle aggregation. The
NIR laser at 0.9-1.1 W/cm2 for 10-15 minutes has been proved to maximize control of
tumor growth in mice and minimize damage to surrounding cells.31 It was also found that
after exposing the cancer cell with NIR laser when incubated with Au nanorods, the
efficacy of nanorods was intensified due to the increased efficiency of NIR absorption and
photothermal conversion.32 The hyperthermia effects, which increased the temperature to
41.5 oC, could be induced by exposing the NIR laser on the gold nanoparticles in the mice,
which finally decreased the tumor volume.33 Moreover, the apoptosis of cancer cells was
also found to be evident after a combination of using the NIR laser at 1 W/cm2 and gold
nanoparticles.34 The results indicated that after using the NIR laser on the cells with AuFe3O4 nanoparticles, they can increase the cell death due to the hyperthermia effects.
However, these nanoparticles need specific targeting ability to reach the tumor site because
some nanoparticles were found in other organs from in vivo studies.33
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5. CONCLUSION
We have developed a fast and simple technique to coat the surface using
biopolymers. The thin layer (1.81 ± 0.60 nm) of biopolymer was deposited on the surface
of Au-Fe3O4 nanoparticles. The nanoparticles were uptaken inside the cells. At high
concentration of Au-Fe3O4 nanoparticles at 500 µg/ml, the percentage of dead cells
increased, which indicated the cytotoxic effect of these nanoparticles. In contrast, there was
negligible cytotoxic effect to the cells at lower concentrations. The uncoated Au-Fe3O4
nanoparticles were able to use for cancer treatment by inducing hyperthermia effects to
cells after exposing the cell with Au-Fe3O4 nanoparticles with NIR laser. These results
recommend the optimal concentrations of using the Au-Fe3O4 nanoparticles to use in the
study of induced hyperthermia effects for cancer therapy and show that our Au-Fe3O4
nanoparticles can be used to treat the cancer by inducing hyperthermia effects to cancer
cells. However, future studies are needed, including studies on the stability study of the
nanoparticles, the amount of each polymer quantification, and in vitro studies of
hyperthermia effect.
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SECTION
2. CONCLUSIONS AND FUTURE WORKS
In this study, polymer-coated anticancer drug-encapsulated NRs were prepared by
the solvent diffusion method. The mean size of PCL-coated CPT NRs was 500.9 ± 91.3
nm in length and 122.7 ± 10.1 nm in width. The anticancer drug-encapsulated NRs have
the ability to degrade in the acidic environment present in tumor sites. Then, the released
drug diffuses into the pores of the polymer and then into cancer cells. In this study, the
conjugation of TTZ on NRs enabled the NRs to specifically target only the breast cancer
cells. It was found that the specific targeting anticancer drug-encapsulated NRs
significantly inhibited the BT-474 breast cancer cell growth. Although in vitro studies
showed high possibility to inhibit breast cancer cell growth, this study still needs evidence
from in vivo studies for therapeutic efficacy.
In addition, biopolymer coating on the surface of Au-Fe3O4 nanoparticles is one
technique to solve the aggregation problem of these nanoparticles. Coating biopolymer on
nanoparticles provide advantages for biomedical applications, especially for drug delivery.
Therefore, the study of coating polymer on nanoparticles rather than using the drug as drugencapsulated nanoparticles might be able to increase the potential of nanoparticles such as
gold nanoparticles, which are used in early detection of cancers and cancer therapy. The
study showed the feasibility study of using Au-Fe3O4 nanoparticles with the principal of
thermal therapy; however, the further studies are needed for more evidence, such as the
quantification of PLL and PEG on the surface of nanoparticles, in vitro studies of using
NIR laser to induce cell apoptosis by the hyperthermia effect, and in vivo studies for
treatment efficacy.
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